Cardiovascular protection in type 2 diabetesAug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Video navigation menu
- Two classes of drugs may protect patients with type 2 diabetes from CV events 00:42
- SGLT2 inhibitors: results of EMPA-REG OUTCOME 01:31
- GLP1 receptor agonists: results of LEADER 02:31
- Differences in effect between SGLT2 inhibitors and GLP1 agonists 03:04
- Cardiologists can choose drugs for CV protection depending on the type of patient 03:40
Persons with type 2 diabetes are at an elevated risk for cardiovascular disease. Results of several recent cardiovascular outcomes trials indicate that two classes of drugs may have cardiovascular benefits in T2DM. This recording aims to highlight the practical implications of these trials.
Prof. Lars Rydén, Professor Emeritus of Cardiology, Karolinska Institute, Stockholm, Sweden
Prof. Rydén is a specialist in internal medicine and cardiology. His research focuses on arrhythmias, cardiac pacing, heart failure and cardiovascular disease related to diabetes. Professor Rydén has published over 500 scientific papers in these fields, and is an honorary member of the Royal College of Physicians London, and several national cardiac societies.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.